Rating Change
Leerink Partners reiterated its Outperform rating on United Therapeutics Corporation (NASDAQ:UTHR) on October 19, 2026.
reiterateNASDAQ:UTHR
Leerink Partners Reiterates Outperform Rating on United Therapeutics Corporation (UTHR)
Leerink Partners reiterated its Outperform rating on United Therapeutics Corporation (NASDAQ:UTHR) on October 19, 2026.
At publication ·
What changed
United Therapeutics Corporation (NASDAQ:UTHR) · reiterate
- Firm
- Leerink Partners
- Rating
- Outperform to Outperform
- Price at event
- $540.67
- Market capitalization
- $21.8B
At a glance
Key takeaways
- Leerink Partners reiterated an Outperform rating on United Therapeutics (UTHR) on October 19, 2026.
Market Context
United Therapeutics Corporation operates in the Healthcare sector. The stock currently trades at $540.67 with a market capitalization of $21.8B. The stock has gained 23.2% over the past 52 weeks.
Analyst coverage from Leerink Partners provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for United Therapeutics Corporation.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for United Therapeutics Corporation
Among the 10 most recent ratings: 7 Buy, 2 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 19, 2026 | Leerink Partners | Outperform | N/A |
| Oct 08, 2026 | RBC Capital | Outperform | N/A |
| Oct 07, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Oct 01, 2026 | BTIG | Buy | N/A |
| Sep 24, 2026 | Goldman Sachs | Sell | N/A |
Related Tools: Analyst Ratings Dashboard | View UTHR Stock Page
Frequently Asked Questions
What does the Outperform rating mean for UTHR?
A rating of Outperform from Leerink Partners reflects the analyst's outlook on United Therapeutics Corporation (NASDAQ:UTHR). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the UTHR forecast page.